Recombinant antibodies: From the laboratory to the clinic

被引：20

作者：

Albrecht, Huguette ^{[1
]}

DeNardo, Sally J. ^{[1
]}

机构：

[1] Univ Calif Davis, Med Ctr, Sacramento, CA 95816 USA

来源：

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2006年 / 21卷 / 04期

关键词：

recombinant antibody fragments; antibody-targeted therapy; pretargeting; immunoconjugates; immunoparticles; therapeutic index;

D O I：

10.1089/cbr.2006.21.285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of recombinant antibodies has facilitated the exploitation of the Ab-Ag interaction specificity for targeted therapies. A fully human antibody, with custom integrated designs, can be obtained in one-third the time, compared to development of antibodies by hybridoma technology. Recombinant antibodies can be tailored for specific applications, "armed" with cytotoxic agents in a controllable fashion, and used for extracellular and intracellular targeting. Multitargeted and combination therapies are rapidly evolving for the treatment of cancer. Antibody therapeutics, costly to develop and produce, have proven beneficial in the clinic.

引用

页码：285 / 304

页数：20

共 141 条

[21] Bispecific human IgG by design [J].

Carter, P .

JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) :7-15

[22]

Chang CH, 2002, MOL CANCER THER, V1, P553

[23] Antibodies with infinite affinity [J].

Chmura, AJ ;

Orton, MS ;

Meares, CF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8480-8484

[24] Efficient cancer therapy with a nanobody-based conjugate [J].

Cortez-Retamozo, V ;

Backmann, N ;

Senter, PD ;

Wernery, U ;

De Baetselier, P ;

Muyldermans, S ;

Revets, H .

CANCER RESEARCH, 2004, 64 (08) :2853-2857

[25] Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants [J].

Daniell, H ;

Streatfield, SJ ;

Wycoff, K .

TRENDS IN PLANT SCIENCE, 2001, 6 (05) :219-226

[26]

DELGADO C, 1992, CRIT REV THER DRUG, V9, P249

[27] Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs) [J].

DeNardo, GL .

SEMINARS IN NUCLEAR MEDICINE, 2005, 35 (03) :202-211

[28] Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted Radioimmunotherapy for metastatic prostate cancer [J].

DeNardo, SJ ;

Richman, CM ;

Albrecht, H ;

Burke, PA ;

Natarajan, A ;

Yuan, A ;

Gregg, JP ;

O'Donnel, RT ;

DeNardo, GL .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7187S-7194S

[29] Development of tumor targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy [J].

DeNardo, SJ ;

DeNardo, GL ;

Miers, LA ;

Natarajan, A ;

Foreman, AR ;

Gruettner, C ;

Adamson, GN ;

Ivkov, R .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7087S-7092S

[30] Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma [J].

DiJoseph, JF ;

Dougher, MM ;

Kalyandrug, LB ;

Armellino, DC ;

Boghaert, ER ;

Hamann, PR ;

Moran, JK ;

Damle, NK .

CLINICAL CANCER RESEARCH, 2006, 12 (01) :242-249

← 1 2 3 4 5 6 7 8 9 10 →